Sales of antimicrobials for veterinary use, Bangladesh, 2023 Authors: SM Sabrina Yesmin, Delfy Góchez, Tanvir Ahmed, Mohammad Nayeem Golder, Pondpan Suwanthada, Niels Frederik Fabricius, Mahbub Hossain, ATM Golam Kibria Khan, Romel Mullick, Md Shariful Islam, Umme Habiba, Aninda Rahman, Md Ashraf Hossain, Md Shameem Haidar Published: 2026 ABSTRACT AbstractObjectiveTo estimate the volume and patterns of antimicrobial sale for food-producing animals in Bangladesh and to provide evidence to support national policy decisions.MethodsWe used the World Organisation for Animal Health tool (animal antimicrobial use calculation module) for data collection and calculation of quantities of antimicrobials used in animals. We collected data on the overall amount of antimicrobials sold for use in food-producing animals, disaggregated by antimicrobial class, active molecule and route of administration.FindingsIn 2023, 475 750 kg of antimicrobials were sold for use in animals across 301 products and 38 molecules. Oral administration accounted for 95.91% (456 301/475 750) of total antimicrobials sold. Tetracyclines were the most sold antimicrobial class, accounting for 32.22% (153 274/475 750) of antimicrobials sold for use in food-producing animals. The second most-sold class was aminoglycosides at 19.77% (94 044/475 750) of total sales. As regards to active molecules, chlortetracycline, neomycin, ceftriaxone, oxytetracycline, metronidazole, sulfamethoxazole, ciprofloxacin and enrofloxacin accounted for 79.34% (377 438/475 749) of the total national antimicrobial sale. Just over one fifth of the antimicrobials sold belong to classes considered to be highest priority critically important antimicrobials for humans (according to the World Health Organization’s list). These classes were third- and fourth-generation cephalosporins, fluoroquinolones, other quinolones and polymyxins.ConclusionOur findings highlight antimicrobial overuse and misuse in food-producing animals in Bangladesh and the need for policy interventions to combat antimicrobial resistance. Our report provides baseline data to support Bangladesh’s National action plan on antimicrobial resistance and enable evidence-based policy development and strengthening of antimicrobial stewardship in the veterinary sector. Introduction Widespread use of antimicrobials in humans and animals can lead to antimicrobial resistance and multidrug resistance in microorganisms. Estimating antimicrobial use, particularly in the veterinary sector, is important to reduce antimicrobial resistance, as this information provides the evidence needed to guide stewardship policies and regulatory interventions. Surveillance of antimicrobial resistance and antimicrobial use is essential to understand and address the problem and its impact on public health,1 as antimicrobial resistance and antimicrobial use are highly correlated.2 From an economic perspective, a loss in global gross domestic product of 575 billion United States dollars in food-producing animals due to antimicrobial resistance is projected by 2050.3 The indiscriminate use of antimicrobials in animals may be a key contributing factor to bacterial antimicrobial resistance.4 However, surveillance and data collection for antimicrobial use are insufficient,5 highlighting the global gap in reliable, country-level estimates of antimicrobial consumption in animals. Monitoring antimicrobial use in animals is essential to track progress in reducing farming’s unnecessary reliance on antimicrobials and to identify gaps in antimicrobial stewardship to combat antimicrobial resistance.6 Global monitoring is also necessary to ensure a One Health approach,7 where interactions occur between human, animal and environmental health.8 In the ninth round of data collection, the World Organisation for Animal Health (WOAH) report highlighted several challenges to conducting surveillance of antimicrobial use across countries.9 These challenges include a lack of information technology tools and human resources; limited coordination between national authorities and the private sector; inadequate regulatory frameworks; insufficient regulatory enforcement; and political instability.9 Currently, most existing global estimates rely on modelled or aggregated data, with limited representation from low- and middle-income countries, including Bangladesh. This situation limits the ability of policy-makers to develop policies based on national evidence. Antimicrobial use in livestock systems in South-East Asia is high and driven by farm profitability, disease prevention and mortality reduction.10 A 2023 literature review showed that the widespread use of medically important antibiotics is high in South-East Asia in livestock, poultry and aquaculture fish.11 Bangladesh has about 402.56 million livestock12 and 0.15 million commercial poultry farms, and 94.17% (113/120) of farmers use antibiotics in their farms.13 As in other low- and middle-income countries, Bangladesh industries producing terrestrial and aquatic food-animals are increasing to meet the growing demand for animal-source nutrition, resulting in increased use of antimicrobial medicines.14 This rising demand further reinforces the need for systematic quantification of veterinary antimicrobial use to inform national and global strategies to reduce antimicrobial resistance. A study on meat-producing animals in Bangladesh found worrying prevalence rates of Salmonella spp. contamination in meat samples which demonstrated multidrug resistance. This resistance could be transmitted to humans through food or via environmental spread.15 Bangladesh is a medicine-manufacturing country and most of its pharmaceutical demand is met through local production. While this situation ensures accessibility, it also contributes to the widespread availability of antimicrobials, which may facilitate irrational use and environmental contamination, further accelerating the development of antimicrobial resistance.16 Additionally, due to inadequate microbial diagnostics facilities in Bangladesh, veterinarians empirically treat animals with antibiotics based on a presumptive diagnosis.17 Despite these risks, Bangladesh currently lacks comprehensive, nationally representative data on veterinary antimicrobial use. The National Strategy and Action Plan for Antimicrobial Resistance Containment in Bangladesh (2023–2028) emphasizes the establishment of national surveillance of antimicrobial use for veterinary medicine.18 The Directorate General of Drug Administration, as the national regulatory authority of drugs, took the initiative to conduct surveillance of veterinary antimicrobial use in collaboration with the Department of Livestock Services. The objective of this surveillance study was to use antimicrobial sales data as a proxy to estimate the volume and patterns of antimicrobial use in food-producing animals in Bangladesh, to provide evidence to support national policy decisions to contain antimicrobial overuse and to contribute to the global reporting efforts. Methods To undertake the surveillance of national sales of antimicrobials for veterinary use, we used the WOAH tool (Animal antimicrobial use calculation module).19 This tool allows the collection and calculation of quantities of antimicrobials used in animals, and provides standardized processes for monitoring patterns of antimicrobial use in animals. For data collection and calculation, we applied WOAH reporting option 3,9,19 which represents the overall amount of antimicrobials sold for and/or used in animals by antimicrobial class, with the possibility to separate by type of use, species group and route of administration. We collected data using pharmaceutical (local manufacturers and importers) sales distribution channels through wholesalers for the year 2023. We collected the sales data from the distribution channels of 29 local manufacturers and importers. These data represent an estimated 90% of the total registered veterinary antimicrobial products in the country, and constitute the most comprehensive nationally available data set on veterinary antimicrobial supply. For products containing multiple antimicrobial agents (fixed-dose combinations), we disaggregated each active ingredient and quantified them separately according to its declared strength on the product label. Thereafter we classified the product into its respective antimicrobial class following WOAH guidelines.19 Antibiotic use for growth promotion of animals is not allowed in Bangladesh; therefore, only therapeutic uses are reported to WOAH. We reported quantities in kilograms of chemical compound as stated on the product label. The estimation process was as follows: (i) we obtained raw sales data (number of units sold per product); (ii) we converted these data into quantities (kg) of active antimicrobial ingredient using product strength; and (iii) we aggregated the total quantities across products and antimicrobial classes to produce national estimates. We converted sales volumes (e.g. number of units sold) into total active ingredient quantities by multiplying the unit strength by the number of units sold. When data were provided in international units, we used standardized conversion factors to express quantities in kilograms of active ingredient.20 We aggregated total antimicrobial volumes by antimicrobial class and animal sector. We standardized information on antimicrobial agents used in animals relative to animal biomass using the following equation: antimicrobial use (mg/kg) = total amount of antimicrobial agents (mg)/total animal biomass (kg). Biomass calculation We calculated animal biomass using the WOAH information system and the Food and Agriculture Organization of the United Nations (FAO) statistics data sets, which represent the total weight of animals exposed to antimicrobial use.21 Specifically, we estimated animal biomass by multiplying the number of animals in each category by standard average live weights as defined in WOAH guidelines. Table 1 gives animal population data and biomass data for 2023 for Bangladesh. Table 1Animal biomass by animal group and category, Bangladesh, 2023 Animal group and category Live animals, no.Slaughtered animals, no.Meat weight, kgMean live weight, kgBiomass, kga Terrestrial Broiler chickens319 689 000323 992 000226 753.21.0323 992 000Buffalo1 516 00088 0257 042.0148.1224 519 600Cattle24 856 0002 792 498203 220.5134.82 812 819 298Ducks66 016 00064 156 00064 155.61.489 818 400Goats26 945 00013 472 500240 782.438.01 201 747 000Sheep3 827 0001 033 3006 199.812.8242 846 240 Aquatic Crustaceans (aquaculture)NANA165 937.0NA165 937 000Fish (aquaculture)NANA2 407 847.0NA2 407 847 000 Total NANANANA 7 469 526 538 NA: not applicable. a We estimated biomass using World Organisation for Animal Health methodology and species-specific approaches.21 For long-lived livestock (cattle, buffalo, goats and sheep), we derived biomass from census data combined with weighted mean live weights reflecting production structure and slaughter data. For short-cycle species (broiler chickens and ducks), we calculated biomass from annual slaughter numbers multiplied by mean live weight at slaughter. For species with breeding components, biomass includes both slaughtered animals and retained breeding stock using standard assumptions. Note: The data source was the Food and Agriculture Organization of the United Nations.22 Animal biomass by animal group and category, Bangladesh, 2023 NA: not applicable. a We estimated biomass using World Organisation for Animal Health methodology and species-specific approaches.21 For long-lived livestock (cattle, buffalo, goats and sheep), we derived biomass from census data combined with weighted mean live weights reflecting production structure and slaughter data. For short-cycle species (broiler chickens and ducks), we calculated biomass from annual slaughter numbers multiplied by mean live weight at slaughter. For species with breeding components, biomass includes both slaughtered animals and retained breeding stock using standard assumptions. Note: The data source was the Food and Agriculture Organization of the United Nations.22 As the collected data set represented about 90% of national sales, we extrapolated to 100% coverage following the WOAH tool guide by applying a proportional scaling factor.19 This approach assumes that the missing 10% of data follow a similar distribution pattern to the reported data. Results Biomass and antimicrobial quantity The total estimated animal biomass was 7 469 526 538 kg based on 2023 FAO data sets (Table 1). The total sales of antimicrobial quantity of active ingredient adjusted to 100% market coverage was 475 750 kg. Dividing this quantity by animal biomass gives the amount of antimicrobials used per animal biomass (mg/kg) which enables comparison across countries and over time. Thus, the overall amount of antimicrobials used per animal biomass was 63.69 mg/kg. In 2023, antimicrobials sold for veterinary use in Bangladesh included 301 registered products containing 38 antimicrobial molecules. Table 2 presents the amounts of veterinary antimicrobials sold by route of administration and class. Table 2Amount of antimicrobial medicines sold for all animal species, by antimicrobial class and route of administration, Bangladesh, 2023Antimicrobial classAmount of medicine sold, kgAll routesOral routeParenteral routeOther routeAminoglycosidesa94 04491 013224897Amphenicols6 5496 54900Third- and fourth-generation cephalosporins61 45653 21982370Fluoroquinolones36 85132 30245490Lincosamides4 4314 2991330Macrolides25 34225 34200Other quinolones429000Penicillins15 65113 52721240Pleuromutilins1 4531 45300Polymyxins56856800Sulfonamides (including trimethoprim)50 05250 05200Tetracyclines153 275152 3878880Others25 64925 590059 Total 475 749 456 301 18 179 156 a The apparent discrepancies in the totals for aminoglycosides and other quinolones are because four veterinary products did not state the route of administration. Therefore, their totals were added to all routes, but they could not be assigned to any specific route of administration.Note: The data collected represented an estimated 90% of the total registered veterinary antimicrobial products. The amounts were adjusted from 90% to 100% market coverage. Amount of antimicrobial medicines sold for all animal species, by antimicrobial class and route of administration, Bangladesh, 2023 a The apparent discrepancies in the totals for aminoglycosides and other quinolones are because four veterinary products did not state the route of administration. Therefore, their totals were added to all routes, but they could not be assigned to any specific route of administration. Note: The data collected represented an estimated 90% of the total registered veterinary antimicrobial products. The amounts were adjusted from 90% to 100% market coverage. Route of administration Overall, oral administration accounted for 95.91% (456 300/475 750) of total antimicrobial use, followed by parenteral administration at 3.82% (18 179/475 750). Other routes accounted for a very small proportion (< 0.50%). For the oral route of administration, 83.05% (378 973/456 301) of the total oral consumption of antimicrobials was concentrated in five main antimicrobial classes, including tetracyclines (33.40%; 152 387/456 301), aminoglycosides (19.95%; 91 013/456 301), third- and fourth-generation cephalosporins (11.66%; 53 219/456 301), sulfonamides (10.97%; 50 052/456 301) and fluoroquinolones (7.08%; 32 302/456 301). For the parenteral route, 82.70% (15 034/18 179) of use was dominated by third- and fourth-generation cephalosporins (45.31%; 8237/18 179), fluoroquinolones (25.03%; 4549/18 179) and aminoglycosides (12.36%; 2248/18 179), indicating reliance on critically important antimicrobials for injectable use. Antimicrobial class Tetracyclines were the most sold antimicrobial class in Bangladesh, with 153 274 kg, that is 32.22% (153 274/475 750) of total sales. Among tetracyclines, chlortetracycline was the predominant active ingredient, accounting for 78.64% (120 533/153 274) of total tetracycline sold, followed by oxytetracycline at 17.59% (26 965/153 274) and doxycycline at 3.77% (5777/153 274). The second most-sold class was aminoglycosides with 94 044 kg, that is 19.77% (94 044/475 750) of total sales. The main aminoglycosides sold were neomycin at 94.49% (88 864/94 044), followed by gentamicin at 5.44% (5113/94 044) and spectinomycin at 0.07% (67/94 044). Third- and fourth-generation cephalosporins were the third most-sold class with 61 456 kg, that is 12.92% (61 456/475 750) of total sales, with ceftriaxone comprising 99.97% (61 438/61 456) of this class. Active substances At the molecule level, the most commonly sold antimicrobials were chlortetracycline, neomycin, ceftriaxone, oxytetracycline, metronidazole, sulfamethoxazole, ciprofloxacin and enrofloxacin, which collectively accounted for 79.34% (377 438/475 749) of total national antimicrobial sales (Table 3). The polymyxin colistin sulfate accounted for 0.12% (568.27/475 749.02) of the total antimicrobials sold in 2023. Table 3Amount of antimicrobial medicines sold for veterinary use, by class and active ingredient, Bangladesh, 2023Antimicrobial class and active ingredients approved for animalsAmount of active ingredient sold, kg (% of total sold)% within class Aminoglycosides Gentamicin5 112.52 (1.07)5.44Neomycin88 863.51 (18.68)94.49Spectinomycin67.12 (0.01)0.07Streptomycin0.31 (0.00)0.00Subtotal94 043.46 (19.77)NA Amphenicols Florfenicol6 548.33 (1.38)100.00Subtotal6 548.33 (1.38)NA Cephalosporins, third- and fourth-generation Ceftiofur17.28 (0.00)0.03Ceftriaxone61 437.86 (12.91)99.97Subtotal61 455.14 (12.92)NA Fluoroquinolones Ciprofloxacin18 282.45 (3.84)49.61Danofloxacin277.37 (0.06)0.75Enrofloxacin13 374.53 (2.81)36.29Levofloxacin200.27 (0.04)0.54Marbofloxacin4 325.95 (0.91)11.74Norfloxacin390.56 (0.081.06Subtotal36 851.12 (7.75)NA Lincosamides Lincomycin4 431.38 (0.93)100.00Subtotal4 431.38 (0.93)NA Macrolides Erythromycin8 997.77 (1.89)35.51Tilmicosin7 387.58 (1.55)29.15Tylosin7 867.63 (1.65)31.05Tylvalosin1 089.24 (0.23)4.30Subtotal25 342.22 (5.33)NA Other quinolones Flumequine428.84 (0.09)100.00Subtotal428.84 (0.09)NA Others Metronidazole25 649.06 (5.39)100.00Subtotal25 649.06 (5.39)NA Penicillins Amoxicillin13 293.95 (2.79)84.94Amoxicillin + clavulanic acid230.19 (0.05)1.47Ampicillin1 326.86 (0.28)8.48Clavulanic acid799.13 (0.17)5.11Penicillin G0.04 (0.00)0.00Penicillin G procaine0.11 (0.00)0.00Subtotal15 650.29 (3.29)NA Pleuromutilins Tiamulin1 453.55 (0.31)100.00Subtotal1 453.55 (0.31)NA Polymyxins Colistin sulfate568.27 (0.12)100.00Subtotal568.27 (0.12)NA Sulfonamides (including trimethoprim) Sulfachloropyridazine6 813.77 (1.43)13.61Sulfadiazine9 562.09 (2.01)19.10Sulfadimidine767.41 (0.16)1.53Sulfamethoxazole22 333.52 (4.69)44.62Sulfaquinoxaline2 458.72 (0.52)4.91Sulfathiazole321.71 (0.07)0.64Trimethoprim7 795.43 (1.64)15.57Subtotal50 052.65 (10.52)NA Tetracyclines Chlortetracycline120 532.67 (25.34)78.64Doxycycline5 777.34 (1.21)3.77Oxytetracycline26 964.69 (5.67)17.59Subtotal153 274.70 (32.22)NA Total 475 749.02 (100.00) NA NA: not applicable. Note: Inconsistencies arise in some values due to rounding. Amount of antimicrobial medicines sold for veterinary use, by class and active ingredient, Bangladesh, 2023 NA: not applicable. Note: Inconsistencies arise in some values due to rounding. Discussion Surveillance of veterinary antimicrobial medicine sales data is an effective tool to monitor national trends in antimicrobial use, which is important for therapeutic decisions and evaluation of the effect of misuse and overuse of antimicrobials on resistant strains.13 No surveillance system of national antimicrobial use for veterinary medicine exists in Bangladesh. Our surveillance report details sales of antimicrobial for veterinary use in Bangladesh for the year 2023. The Animal Antimicrobial Use Global Database (ANIMUSE) is a digital platform developed by WOAH in 2015 to systematically collect, manage and analyse data on antimicrobial use in animals on an annual basis.19 This tool supports countries in the standardized reporting of antimicrobial quantities through a harmonized framework, improves data quality and transparency, and enables better monitoring and assessment of antimicrobial use. As of April 2026, 49 of 133 countries have made their data publicly available in this database, while the remainder have kept their data confidential.19 Among the 49 countries, the average antimicrobial use was 44.13 mg/kg. Bangladesh reported 57.32 mg/kg based on a 90% sales coverage, which is higher than the reported average of these countries. However, regional comparisons indicate variability: in 2021, countries in South-East Asia and the Western Pacific reported a higher average level (167.6 mg/kg), reflecting substantially greater use in some regional production systems. Thus, while Bangladesh’s antimicrobial use is lower than some regional estimates, it still falls within the range of countries with moderate antimicrobial consumption globally. With the updated animal biomass for 2023, Bangladesh is ranked 35th among 133 countries as of April 2026.19 These findings contribute to global antimicrobial use reporting and fill a data gap for South-East Asia, a region previously underrepresented in global surveillance systems such as the Animal Antimicrobial Use Global Database. In 2022, WOAH reported that tetracyclines (28.29%; 19 983 101.01/70 647 931.6 kg) were the most-sold antimicrobials globally, followed by penicillin (17.75%; 12 539 558.43/70 647 931.6 kg) and macrolides (10.62%; 7 505 502.19/70 647 931.6 kg).9 Our results further show that the high sales of tetracyclines are largely driven by compounds in the class, particularly chlortetracycline and oxytetracycline. In addition, our results show high sales of neomycin, ceftriaxone, sulfamethoxazole, ciprofloxacin, enrofloxacin and other antimicrobials, collectively accounting for almost 80% of total national antimicrobial sales for veterinary medicine. This finding reflects the widespread use and potential overuse of medically important antimicrobials in the veterinary sector of Bangladesh. Furthermore, despite regulatory restrictions, the sale of colistin sulfate (568.27 kg) was identified in our study, although it was banned for veterinary use by the Directorate-General of Drug Administration following the Drug Control Committee decision in March 2022.23 This finding suggests possible continued availability or use through existing supply chains. To ensure the rational use of antibiotic substances, the World Health Organization (WHO) publishes Critically important antimicrobials for human medicine,24 focusing on their use in humans, and WOAH publishes World Organisation for Animal Health list of antimicrobial agents of veterinary importance,25 focusing on their use in animals.26 The United Nations General Assembly highlighted the impact of the use of medically important antimicrobials as growth promoters on antimicrobial resistance in 2024.27 Additionally, the third global high-level ministerial conference on antimicrobial resistance in November 2022 recommended preserving critically important antimicrobials for human medicine and ending the use of medically important antimicrobials for growth promotion in animals.28 Nonetheless, our surveillance study highlights that 20.87% (99 304/475 750) of the total antimicrobial sales belong to classes considered to be among the highest priority critically important antimicrobials in humans (according to the WHO list). These classes in the WOAH online database are third-and fourth-generation cephalosporins, fluoroquinolones, other quinolones and polymyxins.19 In this context, ceftriaxone is considered a WHO highest priority critically important antimicrobial, whereas ceftiofur, a closely related third-generation cephalosporin, is used exclusively in veterinary medicine, highlighting the cross-sectoral risk of selection for resistance between human and animal health systems. Ciprofloxacin is likewise classified as a WHO highest priority critically important antimicrobial within the fluoroquinolone class and is restricted to human medicine use. A study assessing trends between 2019 and 2023, demonstrated that the use of amoxicillin, ciprofloxacin, doxycycline, metronidazole, oxytetracycline and sulfamethoxazole is high both in humans and animals in Bangladesh.29 The Directorate General of Drug Administration banned 34 antibiotics for veterinary use in line with the recommendations of the 250th and 253rd meetings of the Drug Control Committee. All combinations of amoxicillin, ciprofloxacin and doxycycline were banned, but not single-dosage forms.23 This continued use highlights the need for evidence-based policy refinement and stronger regulatory enforcement mechanisms. Globally, third- and fourth-generation cephalosporins accounted for only 0.87% (615 243.4/70 647 931.6 kg) of total antimicrobial use and ranked 16th in the 2022 WOAH antimicrobial use surveillance report.9 In contrast, our study demonstrates that these cephalosporins were the third most commonly sold antimicrobial class in veterinary medicine overall in Bangladesh for all dosage forms. Notably, for parenteral dosage forms, these antimicrobials accounted for almost half of total sales, making them the most frequently sold class in veterinary medicine in Bangladesh. In an antimicrobial susceptibility test where Escherichia coli was isolated from cattle, sheep, chicken and humans, 37.5% of isolates were multidrug-resistant, and in the antimicrobial susceptibility test, E. coli showed the highest resistance to sulfamethoxazole–trimethoprim (71.05%; 108/152), tetracycline (62.50%; 95/152) and ampicillin (61.84%; 94/152).30 A scoping review identified that easy antibiotic access and limited veterinary care are responsible for the inappropriate use of antibiotics in the veterinary sectors of South-East Asia.31 These findings, together with ours, highlight a need for policy-level intervention, field monitoring, regulatory enforcement and an emphasis on establishing adequate microbial diagnostics facilities in Bangladesh. Our study has several limitations that may influence the accuracy and interpretation of the findings. There is a risk of misclassification of multi-ingredient antimicrobial products, which could lead to overestimation or underestimation of specific antimicrobial classes. The use of antimicrobials as growth promoters, particularly through medicated feed, is not fully captured in sales data, resulting in potential underreporting of antimicrobial use. Notably, we used supply data to estimate antimicrobial use which does not account for actual consumption, off-label use, stockpiling or wastage at the farm level, which may affect the accuracy of our antimicrobial use estimates. Additionally, illegal, unofficial or unregulated market channels were not captured, which again may result in an underestimation of total antimicrobial use. In addition, sales data may not correspond to actual consumption due to possible waste, spoilage or losses within the distribution chain. We were unable to provide species-specific estimates of antimicrobial use because most products were indicated for multiple animal species. Additionally, the data source was based on aggregate sales information, which does not allow for disaggregation or accurate attribution of use at the species level. Our study is further constrained by gaps in the surveillance system, including incomplete reporting and limited integration across sectors. Uncertainties in biomass estimation may also affect the accuracy of our calculations of the amount of antimicrobial used per animal biomass and limit comparability with other countries. For example, the use of standardized average live weights from WOAH guidelines may not capture local variations in breeds, production systems and farming practices in Bangladesh. Furthermore, species allocation based on labelled indications and proportional distribution for multispecies products may not represent actual usage patterns. These factors, combined with reliance on secondary data sources (from WOAH and FAO), may introduce a margin of error in the biomass estimates which should be considered when interpreting antimicrobial use normalized by biomass.9 Taken together, these limitations suggest that the reported antimicrobial use values should be interpreted with caution, as they may either underestimate or overestimate the true level of antimicrobial exposure in animal populations in Bangladesh. To conclude, our findings provide important evidence on current antimicrobial use in the animal health sector in Bangladesh. The findings highlight the substantial use of tetracyclines, aminoglycosides, third- and fourth-generation cephalosporins, sulfonamides and fluoroquinolones, indicating widespread reliance on medically important antimicrobials for humans. Importantly, this report provides a baseline data set to support Bangladesh’s National Action Plan on Antimicrobial Resistance and enable evidence-based policy development, prioritization of regulatory interventions and strengthening of antimicrobial stewardship in the veterinary sector. The Directorate General of Drug Administration, Department of Livestock Services and other veterinary authorities can use the results to inform their efforts to refine control measures, update essential drug policies, restrict the use of inappropriate antimicrobial classes and improve enforcement mechanisms, particularly for critically important antimicrobials. In addition, the data establish a baseline for monitoring progress over time and support Bangladesh’s integration into global reporting frameworks such as WOAH’s Animal Antimicrobial Use Database. Finally, the findings underscore the need for coordinated One Health actions involving regulatory authorities, veterinary practitioners, feed industries and farmers to promote prudent and responsible antimicrobial use in veterinary practice and reduce the risk of the emergence of antimicrobial resistance and transmission between animals, humans and the environment in Bangladesh. These actions should be aligned with WHO antimicrobial classification and stewardship principles to preserve the effectiveness of critically important antimicrobials for humans.